Sensitive Nanozyme Test May Provide Rapid Point-of-Care Diagnosis of Ebola
|
By LabMedica International staff writers Posted on 24 Sep 2015 |

Image: In the new nanozyme immunochromatographic strip test for Ebolavirus (EBOV), the magnetic (A) and catalytic (B) properties of the nanozymes (Fe3O4 magnetic nanoparticles (MNPs)) make the signal 100 times stronger than standard strips with colloidal-gold nanoparticles, generating a deeper color reaction that can be more clearly seen by the naked eye (Image courtesy of Duan D et al., 2015, and Elsevier).
Researchers have developed a simple low-cost Ebolavirus (EBOV) test based on detection technology using magnetic nanoparticles that has shown 100x higher sensitivity than the standard immunochromatographic ELISA gold strip test.
In a new study led by Xiyun Yan, professor at the Institute of Biophysics, Chinese Academy of Sciences (Beijing, China), a nanozyme strip test was developed that is similar to the gold strip test but instead uses Fe3O4 magnetic nanoparticles (nanozymes) that enhance the signal via their intrinsic enzyme-like activity. Results showed 100x higher sensitivity than the gold strip test—the new test detects EBOV glycoprotein at concentrations as low as 1 nanogram/mL. Also, to concentrate the virus particles in the sample, the tube bottom is simply held against a magnet, so no expensive lab equipment is needed.
Early accurate detection is a key to controlling the Ebola outbreak as patients can then be isolated and treated. Current tests are either too expensive to be useful where they are most needed, or not sensitive enough to provide accurate diagnosis. PCR testing is highly sensitive but expensive and complicated, requiring specialized skills and equipment. Testing with the ELISA gold strip is inexpensive, but sensitivity is low.
“Our new strip test is a simple, one-step test that is cheap and easy to use, and provides a visible signal, which means people don’t need training to use it. We think it will be especially helpful in rural areas,” said Prof. Yan, “We’re very excited about our new nanozyme test, as it is much more sensitive and you don’t need any specialist equipment to get a quick, accurate result.” Her colleagues at the Chinese Center for Disease Control and Prevention (CDC) will field-test it in West Africa for its EBOV diagnostic and screening potential. The researchers are also developing automatic equipment to reduce risk of test contamination from hand-contact.
The nanozyme test is the result of an interdisciplinary collaboration of scientists and clinicians. The researchers are collaborating to develop this robust technology further as it can be applied for detection of other biological molecules, making it useful to diagnose additional infectious diseases and to potentially detect cancer tumors. It is also being tested for its potential to help in decontamination for wastewater treatment.
“We had an idea and talked to many people about it, and the result is a test that will overcome a problem,” said Prof. Yan, “We have built strong collaborations that have finally made this method successful, and we’re looking forward to applying it to many other areas.”
The study, by Duan D et al., was published online ahead of print 11 May 2015, in the journal Biosensors and Bioelectronics.
Related Links:
Chinese Academy of Sciences
Elsevier
In a new study led by Xiyun Yan, professor at the Institute of Biophysics, Chinese Academy of Sciences (Beijing, China), a nanozyme strip test was developed that is similar to the gold strip test but instead uses Fe3O4 magnetic nanoparticles (nanozymes) that enhance the signal via their intrinsic enzyme-like activity. Results showed 100x higher sensitivity than the gold strip test—the new test detects EBOV glycoprotein at concentrations as low as 1 nanogram/mL. Also, to concentrate the virus particles in the sample, the tube bottom is simply held against a magnet, so no expensive lab equipment is needed.
Early accurate detection is a key to controlling the Ebola outbreak as patients can then be isolated and treated. Current tests are either too expensive to be useful where they are most needed, or not sensitive enough to provide accurate diagnosis. PCR testing is highly sensitive but expensive and complicated, requiring specialized skills and equipment. Testing with the ELISA gold strip is inexpensive, but sensitivity is low.
“Our new strip test is a simple, one-step test that is cheap and easy to use, and provides a visible signal, which means people don’t need training to use it. We think it will be especially helpful in rural areas,” said Prof. Yan, “We’re very excited about our new nanozyme test, as it is much more sensitive and you don’t need any specialist equipment to get a quick, accurate result.” Her colleagues at the Chinese Center for Disease Control and Prevention (CDC) will field-test it in West Africa for its EBOV diagnostic and screening potential. The researchers are also developing automatic equipment to reduce risk of test contamination from hand-contact.
The nanozyme test is the result of an interdisciplinary collaboration of scientists and clinicians. The researchers are collaborating to develop this robust technology further as it can be applied for detection of other biological molecules, making it useful to diagnose additional infectious diseases and to potentially detect cancer tumors. It is also being tested for its potential to help in decontamination for wastewater treatment.
“We had an idea and talked to many people about it, and the result is a test that will overcome a problem,” said Prof. Yan, “We have built strong collaborations that have finally made this method successful, and we’re looking forward to applying it to many other areas.”
The study, by Duan D et al., was published online ahead of print 11 May 2015, in the journal Biosensors and Bioelectronics.
Related Links:
Chinese Academy of Sciences
Elsevier
Latest Microbiology News
- Study Reveals Widespread Community Spread of Drug-Resistant Klebsiella
- Stronger Laboratory Services Support Timely Melioidosis Diagnosis Amid Global Spread
- Extracellular Vesicle Biomarker May Enable Noninvasive Monitoring of H. pylori
- Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE
- New Protein Targets Support Diagnostics for Louse-Borne Relapsing Fever
- TORCH Infection Trends Point to Need for Tailored Screening in Pregnancy
- Automated Blood Culture System Speeds Detection of Bloodstream Infections
- New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
- Gut Microbiome Signatures Help Identify Risk of IBD Progression
- FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
- New AMR Assay Supports Rapid Infection Control Screening in Hospitals
- Diagnostic Gaps Complicate Bundibugyo Ebola Outbreak Response in Congo
- Study Finds Hidden Mpox Infections May Drive Ongoing Spread
- Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals
- Molecular Urine and Stool Tests Do Not Improve Early TB Treatment in Hospitalized HIV Patients
- Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
Channels
Clinical Chemistry
view channel
Rapid Blood Test Aids Diagnosis of Acute Ischemic Stroke
Rapid and accurate differentiation of stroke types remains a persistent challenge in emergency medicine, particularly because early imaging can miss ischemic events that require time-sensitive intervention.... Read more
Maternal Blood Biomarkers Identify Risk of Preterm and Early-Term Birth
Preterm and early-term births can lead to lasting complications because vital organs continue to mature during the final weeks of pregnancy. Babies born too soon face increased risks of breathing difficulties,... Read moreMolecular Diagnostics
view channel
RNA Blood Test May Enable Earlier Alzheimer’s Disease Diagnosis
Alzheimer’s disease affects an estimated 55 million people worldwide and remains difficult to diagnose at an early stage. Diagnostic workups can be complicated by symptom overlap with other conditions,... Read more
AI Reasoning Model Generates Diagnostic Leads for Unresolved Rare Disease Cases
Rare genetic diseases often leave families without definitive answers, even after genome sequencing and expert review. As scientific evidence evolves and clinical data remain fragmented across systems,... Read more
Point-of-Care Molecular Test Detects Group A Strep in Minutes
Group A Streptococcus is a leading bacterial cause of acute pharyngitis and a common reason for outpatient visits, accounting for millions of healthcare encounters each year. Because symptoms of bacterial... Read more
Genetic Testing and Surveillance Cuts Costs and Improves Survival in Li-Fraumeni Syndrome
Inherited cancer predisposition syndromes such as Li-Fraumeni syndrome (LFS) can lead to diverse, early-onset tumors and require intensive, lifelong surveillance. Balancing timely identification with sustainable... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Lab-on-a-Chip Approach Advances Immune–Cancer Cell Interaction Analysis
Conventional cytotoxicity assays often average responses across thousands of cells, obscuring how individual immune cells engage and kill tumor cells. For immunotherapy evaluation, the precise sequence... Read more
Antibody Profiles Provide Clues to Long COVID Severity and Symptoms
Persistent symptoms after acute COVID-19 affect millions of people, causing fatigue, respiratory issues, and cognitive deficits that can be difficult to quantify with standard tests. Clinical teams lack... Read morePathology
view channel
Stain-Free Imaging Platform Matches Standard Cancer Pathology
Histopathology underpins cancer diagnosis, but turnaround times and inter-laboratory variability can limit timely, consistent interpretation. Conventional staining relies on chemical dyes and multiple... Read more
New Companion Diagnostic Expands Precision Medicine in Prostate Cancer
Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer
Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Partnership Aims to Improve Transplant Monitoring Across Care Continuum
Allograft rejection and chronic graft dysfunction remain major challenges in solid organ transplantation, requiring careful immunologic matching and long-term surveillance. Fragmented pre- and post-transplant... Read more
QIAGEN Enhances QIAcuity Platform with Gene Expression and Multiplexing Tools
QIAGEN (Venlo, Netherlands) has introduced additions to its QIAcuity dPCR ecosystem that focus on gene expression, expanded assay content, and workflow standardization for life sciences and biopharma users.... Read more








